©2017 by Dani Offen’s Laboratory for Translational Neuroscience. Proudly created with Wix.com

PUBLICATIONS

 

 

2010

​

Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O.

EPMA J. 2010 Jun;1(2):343-61. doi: 10.1007/s13167-010-0026-1.

​

​

 

Neurogenesis in the aged and neurodegenerative brain.

Shruster A, Melamed E, Offen D.

Apoptosis. 2010 Nov;15(11):1415-21. doi: 10.1007/s10495-010-0491-y. Review.

​

​

 

Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels.

Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y.

NMR Biomed. 2010 Feb;23(2):196-206. doi: 10.1002/nbm.1443.

​

​

 

Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis.

Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D.

J Mol Neurosci. 2010 May;41(1):129-37. doi: 10.1007/s12031-009-9302-8. 

​

​

2009

​

 

Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.

Sadan O, Melamed E, Offen D.

Expert Opin Biol Ther. 2009 Dec;9(12):1487-97. doi: 10.1517/14712590903321439. Review.

​

​

 

Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases.

Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D.

Isr Med Assoc J. 2009 Apr;11(4):201-4.

​

​

Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible.

Barzilay R, Melamed E, Offen D.

Stem Cells. 2009 Oct;27(10):2509-15. doi: 10.1002/stem.172. Review.

​

​

 

Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains.

Barzilay R, Sadan O, Melamed E, Offen D.

Cytotherapy. 2009;11(4):435-42. doi: 10.1080/14653240902849796.

​

​

 

Accelerated proteasomal activity induced by Pb2+, Ga3+, or Cu2+ exposure does not induce degradation of alpha-synuclein.

Grunberg-Etkovitz N, Lev N, Ickowicz D, Avital A, Offen D, Malik Z.

J Environ Pathol Toxicol Oncol. 2009;28(1):5-24.

​

​

 

Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells.

Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D.

Stem Cells Dev. 2009 May;18(4):591-601. doi: 10.1089/scd.2008.0138.

​

​

Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.

Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D.

Stem Cells Dev. 2009 Oct;18(8):1179-90. doi: 10.1089/scd.2008.0411.

​

​

Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.

Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D.

J Mol Neurosci. 2009 Sep;39(1-2):199-210. doi: 10.1007/s12031-008-9166-3.

​

​

DJ-1 protects against dopamine toxicity.

Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D.

J Neural Transm (Vienna). 2009 Feb;116(2):151-60. doi: 10.1007/s00702-008-0134-4.

​

 

DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS.

Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D.

J Mol Neurosci. 2009 Jun;38(2):94-102. doi: 10.1007/s12031-008-9138-7.

​

​​

Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant.

Offen D, Barhum Y, Melamed E, Embacher N, Schindler C, Ransmayr G.

J Mol Neurosci. 2009 Jun;38(2):85-93. doi: 10.1007/s12031-007-9004-z.

​

 

2008

​

Progressive damage along the optic nerve following induction of crush injury or rodent anterior ischemic optic neuropathy in transgenic mice.

Dratviman-Storobinsky O, Hasanreisoglu M, Offen D, Barhum Y, Weinberger D, Goldenberg-Cohen N.

Mol Vis. 2008;14:2171-9. 

​

Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging.

Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D.

Stem Cells. 2008 Oct;26(10):2542-51. doi: 10.1634/stemcells.2008-0240. 

​

​

Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease.

Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D.

Cytotherapy. 2008;10(4):340-52. doi: 10.1080/14653240802021330.

​

​

Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols.

Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D.

Stem Cells Dev. 2008 Jun;17(3):547-54. doi: 10.1089/scd.2007.0172.

​

​

Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.

Lev N, Ickowicz D, Melamed E, Offen D.

Neurotoxicology. 2008 May;29(3):397-405. doi: 10.1016/j.neuro.2008.01.007.

​

​

2007

​

Toxic causes of parkinsonism.

Lev N, Melamed E, Offen D.

Handb Clin Neurol. 2007;84:385-98. doi: 10.1016/S0072-9752(07)84050-4.

 

​

 

Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease.

Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E.

J Neural Transm Suppl. 2007;(72):133-43.

​

​

Role of DJ-1 in parkinson's disease.

Lev N, Roncevich D, Ickowicz D, Melamed E, Offen D.

J Mol Neurosci. 2007 Mar;31(3):307. 

​

​

 

Bax ablation protects against hepatic ischemia/reperfusion injury in transgenic mice.

Ben-Ari Z, Pappo O, Cheporko Y, Yasovich N, Offen D, Shainberg A, Leshem D, Sulkes J, Vidne BA, Hochhauser E.

Liver Transpl. 2007 Aug;13(8):1181-8.

​

​

 

Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases.

Kan I, Melamed E, Offen D.

Handb Exp Pharmacol. 2007;(180):219-42. Review.

​

​

 

Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression.

Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D.

Neurosci Lett. 2007 May 23;419(1):28-33. Epub 2007 Apr 13.

​

​

 

Bax deficiency reduces infarct size and improves long-term function after myocardial infarction.

Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y, Pannet H, Tobar A, Vidne BA, Birk E.

Cell Biochem Biophys. 2007;47(1):11-20.

​

​

 

Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation.

Kan I, Melamed E, Offen D, Green P.

J Lipid Res. 2007 Mar;48(3):513-7.

​

​

 

Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.

Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D.

Exp Neurol. 2007 Mar;204(1):260-3.

​

​

2006

 

Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis.

Lev N, Ickowicz D, Barhum Y, Blondheim N, Melamed E, Offen D.

Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):1987-95.

​

​

 

Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.

Gilgun-Sherki Y, Melamed E, Offen D.

Curr Pharm Des. 2006;12(27):3509-19. Review.

​

​

 

Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.

Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, Barzilai R, Bahat-Stromza M, Barhum Y, Bulvik S, Melamed E, Offen D.

Stem Cells Dev. 2006 Apr;15(2):141-64.

​

​

 

Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.

Lev N, Melamed E, Offen D.

Neurosci Lett. 2006 May 15;399(1-2):27-32. Epub 2006 Apr 11.

​

​

 

Adult stem cells for neuronal repair.

Barzilay R, Levy YS, Melamed E, Offen D.

Isr Med Assoc J. 2006 Jan;8(1):61-6. Review.

​

​

Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents.

Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D.

Neurosci Lett. 2006 Mar 6;395(2):124-8. Epub 2005 Dec 15.

​

​

2005

​

 

A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.

Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D.

Clin Neuropharmacol. 2005 Nov-Dec;28(6):285-8.

​

​

 

Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.

Gilgun-Sherki Y, Barhum Y, Atlas D, Melamed E, Offen D.

J Mol Neurosci. 2005;27(1):125-35.

​

​

Therapeutic potential of neurotrophic factors in neurodegenerative diseases.

Levy YS, Gilgun-Sherki Y, Melamed E, Offen D.

BioDrugs. 2005;19(2):97-127. Review.

​

​

A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.

Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E.

Eur J Neurosci. 2005 Feb;21(3):637-46.

​

​

Integral therapeutic potential of bone marrow mesenchymal stem cells.

Kan I, Melamed E, Offen D.

Curr Drug Targets. 2005 Feb;6(1):31-41. Review.

​

​

2004

​

Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.

Elkon H, Melamed E, Offen D.

J Mol Neurosci. 2004;24(3):387-400.

​

​

Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Levy YS, Stroomza M, Melamed E, Offen D.

J Mol Neurosci. 2004;24(3):353-86. Review.

​

​

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.

Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D.

Pharmacogenomics J. 2004;4(5):291-306. Review.

​

​

 

A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis.

Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D.

J Neurochem. 2004 Jun;89(5):1241-51.

​

​

Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.

Lev N, Barhum Y, Melamed E, Offen D.

Neurosci Lett. 2004 Apr 15;359(3):139-42.

​

​

 

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.

Gilgun-Sherki Y, Melamed E, Offen D.

J Neurol. 2004 Mar;251(3):261-8. Review.

​

2003

​

 

Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells.

Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D.

J Mol Neurosci. 2003;21(2):121-32.

​

​

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.

Gilgun-Sherki Y, Panet H, Melamed E, Offen D.

Brain Res. 2003 Nov 7;989(2):196-204.

​

​

 

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis.

Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D.

Neurosci Res. 2003 Oct;47(2):201-7.

​

​

 

Antioxidant treatment in Alzheimer's disease: current state.

Gilgun-Sherki Y, Melamed E, Offen D.

J Mol Neurosci. 2003;21(1):1-11. Review.

​

​

 

The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.

Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D.

Pharmacol Toxicol. 2003 Aug;93(2):66-70.

​

​

 

Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.

Gilgun-Sherki Y, Melamed E, Ziv I, Offen D.

Pharmacol Toxicol. 2003 Jul;93(1):54-6. 

​

​

 

Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice.

Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA.

Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2351-9.

​

​

Apoptosis and Parkinson's disease.

Lev N, Melamed E, Offen D.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):245-50. Review.

​

​

The molecular mechanisms of dopamine toxicity.

Barzilai A, Daily D, Zilkha-Falb R, Ziv I, Offen D, Melamed E, Shirvan A.

Adv Neurol. 2003;91:73-82. Review.

​

​

2002

​

Hemin-induced apoptosis in PC12 and neuroblastoma cells: implications for local neuronal death associated with intracerebral hemorrhage.

Levy YS, Streifler JY, Panet H, Melamed E, Offen D.

Neurotox Res. 2002 Nov-Dec;4(7-8):609-616.

 

​

Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.

Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D.

J Mol Neurosci. 2002 Jun;18(3):229-38.

​

​

Antioxidant therapy in acute central nervous system injury: current state.

Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D.

Pharmacol Rev. 2002 Jun;54(2):271-84. Review.

​

​

2001

​

6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.

Elkon H, Melamed E, Offen D.

Cell Mol Neurobiol. 2001 Dec;21(6):771-81.

​

​

Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease.

Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I.

Neurosci Lett. 2001 Dec 28;316(3):129-32.

​

​

Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.

Gilgun-Sherki Y, Melamed E, Offen D.

Neuropharmacology. 2001 Jun;40(8):959-75. Review.

​

​

Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells.

Panet H, Barzilai A, Daily D, Melamed E, Offen D.

J Neurochem. 2001 Apr;77(2):391-8.

​

​

Catechol-O-methyltransferase decreases levodopa toxicity in vitro.

Offen D, Panet H, Galili-Mosberg R, Melamed E.

Clin Neuropharmacol. 2001 Jan-Feb;24(1):27-30.

​

​

Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways.

Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A.

J Biol Chem. 2001 Jun 15;276(24):21618-26.

​

​

Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2837-42.

​

​

Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease.

Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E.

Methods Mol Med. 2001;62:73-87. doi: 10.1385/1-59259-142-6:73.

​

​